Saturday, September 12, 2020 1:50:20 PM
Right. I was only pointing to Phase IIb/III trials currently underway based on the Chairman's interview. That's all.
On the 60% to 70% the statement by itself shows huge confidence. I've not seen any top executive/management of a bio-tech company sticking out his/her neck to say this: probability of the FDA approval is 60% to 70%. Not many anyway.
$RLFTF
Disclaimer: Imho only, do your own dd.
On the 60% to 70% the statement by itself shows huge confidence. I've not seen any top executive/management of a bio-tech company sticking out his/her neck to say this: probability of the FDA approval is 60% to 70%. Not many anyway.
$RLFTF
Disclaimer: Imho only, do your own dd.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
